All In Biotech

Investigational drug · Phase 3

Olvi-Vec

Also called: olvimulogene nanivacirepvec, GL-ONC, GLV-1h68

Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Advanced Non-squamous Non-small-cell Lung Cancer, Advanced Squamous Non-Small Cell Lung Carcinoma, Metastatic Non-squamous Non Small Cell Lung Cancer.

Phase 3

Last checked: Nov 19, 2026Latest source record: Aug 26, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

3

3 still active

All registered trials

4

Any phase or sponsor naming "Olvi-Vec"

First trial start

2022

Aug 31, 2022

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "Olvi-Vec", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Advanced Non-squamous Non-small-cell Lung Cancer
  • Advanced Squamous Non-Small Cell Lung Carcinoma
  • Metastatic Non-squamous Non Small Cell Lung Cancer
  • Metastatic Squamous Non-Small Cell Lung Carcinoma
  • Non-small Cell Lung Cancer
  • Non-small Cell Lung Cancer Stage III
  • Non-small Cell Lung Cancer Stage IV
  • Non-small Cell Lung Cancer Recurrent
  • SCLC, Extensive Stage
  • Platinum-resistant Ovarian Cancer

Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Ovarian cancer · Oncology

Largest trials

Live from ClinicalTrials.gov: studies naming "Olvi-Vec" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 55 on PubMed

Also in development for Advanced Non-squamous Non-small-cell Lung Cancer

  • JAB-3312Phase 32 trials

    Allist Pharmaceuticals, Inc. · KRAS P.G12C, Non-small Cell Lung Cancer, Colorectal Cancer

  • Genelux Corporation · Advanced Non-squamous Non-small-cell Lung Cancer, Advanced Squamous Non-Small Cell Lung Carcinoma, Metastatic Non-squamous Non Small Cell Lung Cancer

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.